EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Repigmentation Response Trajectories With Ruxolitinib Cream in Patients With Nonsegmental Vitiligo: Pooled Analysis From 104-Week TRuE-V Phase 3 Studies

Seemal R. Desai, Andrew Blauvelt, Daniel Sturm, Haobo Ren, David Rosmarin

SKIN The Journal of Cutaneous Medicine · 10.11.2026 · 10 (6) · s899

DOI: 10.25251/kv1dfm54 ↗

Kurz gefasst

Fachartikel in der Zeitschrift SKIN The Journal of Cutaneous Medicine, online erschienen am 10.11.2026. Verfasst von Seemal R. Desai und 4 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Long-term results from the phase 3 TRuE-V program showed continued repigmentation with ruxolitinib cream through 2 years. This analysis characterized 2-year repigmentation trajectories according to Week 24 response among patients randomized to 1.5% ruxolitinib cream in TRuE-V1/TRuE-V2.

Methods

Patients completing the 52-week TRuE-V1/TRuE-V2 phase 3, randomized, vehicle-controlled studies could enroll in the 52-week TRuE-V long-term extension rollover study. This post hoc analysis included patients who applied 1.5% ruxolitinib cream twice daily from Day 1 through Week 104. Patients were stratified by Week 24 response: ≥25%/≥50%/≥75%/≥90% improvement in facial and total Vitiligo Area Scoring Index (F‑VASI25/50/75/90 and T‑VASI25/50/75/90). Within each Week 24 response cohort, percentages of patients achieving higher F‑VASI and T‑VASI threshold responses were assessed through Week 104.

Results

At Week 24, 169/126/66/27 patients achieved F‑VASI25/50/75/90, and 117/51/10/2 achieved T‑VASI25/50/75/90. Baseline characteristics were generally comparable between Week 24 F‑VASI and T‑VASI response cohorts, although the T‑VASI75 and T‑VASI90 groups were small, limiting interpretation of potential differences. Among Week 24 F‑VASI25 responders, 89.3%, 60.7%, and 26.8% achieved F‑VASI50, F‑VASI75, and F‑VASI90 at Week 52; respective response rates increased to 95.6%, 78.8%, and 49.6% at Week 104. Among Week 24 F‑VASI50 responders, 69.6% and 32.8% achieved F‑VASI75 and F‑VASI90 at Week 52; these rates increased to 85.7% and 56.1%, respectively, at Week 104. Among Week 24 F‑VASI75 responders, 45.5% and 67.3% achieved F‑VASI90 at Weeks 52 and 104, respectively. Among Week 24 F‑VASI90 responders, 70.4% and 88.9% maintained F‑VASI90 at Weeks 52 and 104, respectively. Comparable trends were observed for T‑VASI. Among Week 24 T‑VASI25 responders, 76.7%, 33.6%, and 7.8% achieved T‑VASI50, T‑VASI75, and T‑VASI90 at Week 52; respective response rates increased to 84.9%, 44.1%, and 14.0% at Week 104. Among Week 24 T‑VASI50 responders, 58.8% and 17.6% achieved T‑VASI75 and T‑VASI90 at Week 52; these rates increased to 65.0% and 20.0%, respectively, at Week 104. Among Week 24 T‑VASI75 responders, 50.0% and 33.3% achieved T‑VASI90 at Weeks 52 and 104, respectively. All Week 24 T‑VASI90 responders maintained T‑VASI90 at Week 52; Week 104 outcomes were unavailable.

Conclusions

Ruxolitinib cream treatment resulted in continued improvements in facial and total body repigmentation through 2 years, regardless of the repigmentation response achieved at Week 24. Across Week 24 response cohorts, percentages of patients achieving higher F-VASI and T-VASI response thresholds (i.e., VASI50, VASI75, and VASI90) increased over 2 years, supporting the benefit of continued treatment.

Zitieren

APA

Desai, S. R., Blauvelt, A., Sturm, D., Ren, H., & Rosmarin, D. (2026). Repigmentation Response Trajectories With Ruxolitinib Cream in Patients With Nonsegmental Vitiligo: Pooled Analysis From 104-Week TRuE-V Phase 3 Studies. SKIN The Journal of Cutaneous Medicine, 10(6), s899. https://doi.org/10.25251/kv1dfm54

Vancouver

Desai SR, Blauvelt A, Sturm D, Ren H, Rosmarin D. Repigmentation Response Trajectories With Ruxolitinib Cream in Patients With Nonsegmental Vitiligo: Pooled Analysis From 104-Week TRuE-V Phase 3 Studies. SKIN The Journal of Cutaneous Medicine. 2026;10(6):s899. doi:10.25251/kv1dfm54

BibTeX
@article{Desai2026,
  author = {Desai, Seemal R. and Blauvelt, Andrew and Sturm, Daniel and Ren, Haobo and Rosmarin, David},
  title = {Repigmentation Response Trajectories With Ruxolitinib Cream in Patients With Nonsegmental Vitiligo: Pooled Analysis From 104-Week TRuE-V Phase 3 Studies},
  journal = {SKIN The Journal of Cutaneous Medicine},
  year = {2026},
  volume = {10},
  number = {6},
  pages = {s899},
  doi = {10.25251/kv1dfm54}
}
Kostenlos starten →